ASH 2022

Acute Lymphoblastic Leukaemia

Blinatumomab candidate for standard-of-care in newly diagnosed B-ALL 

Presented By

Prof. Mark Litzow, Mayo Clinic, MN, USA

Trial

Phase 3, ECOG-ACRIN-E1910 NCTN

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:07

High-dose methotrexate or standard interim maintenance in young patients with ALL? 

Presented By

Ms Amy Kirkwood, University College London, UK

Trial

UKALL 2011

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:01

Acute Myeloid Leukaemia

Excellent results for triplet regimen in FLT3-mutated AML 

Presented By

Prof. Nicholas Short, University of Texas, TX, USA

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:25

MRD by qPCR prognostic of outcomes in venetoclax-treated NPM1-mutated AML 

Presented By

Mr Jad Othman, Guy’s and St Thomas’ NHS Foundation Trust, UK

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:20

Promising results for triplet therapy with magrolimab in AML

Presented By

Prof. Naval Daver, Anderson Cancer Center, TX, USA

Trial

Phase 3, ENHANCE-3

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:17

Should we use intensive chemotherapy prior to allo-HCT in relapsed/refractory AML? 

Presented By

Prof. Matthias Stelljes, University of Muenster, Germany

Trial

Phase 3, EATL3-ASAP

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:13

Chronic Leukaemia

Zanubrutinib wins battle of BTK inhibitors in relapsed or refractory CLL/SLL

Presented By

Prof. Jennifer Brown, Dana Farber Cancer Institute, MA, USA

Trial

Phase 3, ALPINE

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:40

Ibrutinib plus venetoclax displays long-term benefits in CLL 

Presented By

Prof. John Allan, Weill Cornell Medicine, NY, USA

Trial

Phase 2, CAPTIVATE

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:28

Multiple Myeloma

Lymphoma

Myeloproliferative Neoplasms

Efgartigimod successful in immune thrombocytopenia 

Presented By

Prof. Catherine Broome, Georgetown University, Washington DC, USA

Trial

Phase 3, ADVANCE

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:57

INCA033989: novel investigational agent for CALR-mutated MPN

Presented By

Dr Edimara Reis, Incyte Corporation, DE, USA

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:47

Ruxolitinib mediates clonal evolution of RAS pathway mutations in MPN

Presented By

Dr Nabih Maslah, Université Paris Cité, France

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:43

Immune Thrombocytopenia

Various Topics

C1 inhibitor deficiency linked to thrombosis

Presented By

Dr Steven Grover, University of North Carolina, NC, USA

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 13:18

Durable responses to gene therapy in haemophilia A

Presented By

Prof. Stacy Croteau, Harvard Medical School, MA, USA

Trial

Phase 1/2, SPK-8011

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 13:16

Long-term benefits from beti-cel in transfusion-dependent β-thalassaemia

Presented By

Prof. Mark Walters; Prof. Franco Locatelli

Trial

LTF-303

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 13:14

Neutrodiet: non-restricted diet is the preferred option after SCT

Presented By

Prof. Federico Stella, Università degli Studi di Milano, Italy

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 13:11

Iptacopan offers solution for patients with PNH and residual anaemia after standard-of-care 

Presented By

Prof. Régis de Latour, Saint-Louis Hospital, France

Trial

Phase 3, Apply-PNH

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 13:09

Novel therapy may replace standard-of-care prophylaxis for GVHD

Presented By

Prof. Shernan Holtan, University of Minnesota, MN, USA

Trial

Phase 3, BMT CTN 1703

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 13:05

LMWH does not result in higher live birth rates in women with inherited thrombophilia 

Presented By

Prof. Saskia Middeldorp, Radboud UMC, the Netherlands

Trial

ALIFE2

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 13:01